Released May 14, 2026, after the close
10-Q filed May 14, 2026, 44 days after period end · 0001683168-26-003909
Q1 2026 · 10-Q
Revenue—
Net Income-$5.63M-$5.63M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.24-$0.24 N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$5,705,956N/M
Operating Cash Flow-$5,017,327N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$5.63M | -$6.32M | -$8.30M | -$5.27M |
| EPS Diluted | -$0.24 | -$0.32 | -$5.40 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actuate Therapeutics, Inc. · CIK 1652935 · Engraved from SEC EDGAR